NanoVibronix, Inc.
5.57-0.32 (-5.43%)
Oct 29, 4:00:00 PM EDT · NasdaqCM · NAOV · USD
Key Stats
Market Cap
4.85MP/E (TTM)
-Basic EPS (TTM)
-172.70Dividend Yield
0%Recent Filings
8-K
NanoVibronix raises $2M via offering
NanoVibronix closed a $2.0 million registered direct offering on September 16, 2025, selling 74,114 common shares and prefunded warrants for 217,090 shares to one institutional investor at $7.01 per share. Net proceeds of $1.8 million will fund working capital, including debt repayment and preferred stock redemption. This bolsters liquidity while diluting shareholders. Warrants cap ownership at 4.99% or 9.99%.
10-Q
Q2 FY2025 results
NanoVibronix's Q2 FY2025 revenues fell 40% y/y to $494K, yet the ENvue merger in February drove topline momentum with $49K from enteral feeding devices, offsetting a dip in legacy pain therapy sales. Gross loss widened to $35K from $428K profit y/y, pressured by $159K inventory write-off and $186K tech amortization, while operating loss ballooned to $3.98M amid merger integration costs. Cash swelled to $4.0M on $8.2M from Series G preferred raise, with $1.98M debt outstanding; free cash flow not disclosed in the 10-Q. Merger closed February 14, 2025, for $41.9M (stock/warrants), recognizing $38.6M goodwill and $5.9M intangibles (5-7 years). Merger sharpens medtech focus. Nasdaq delisting looms if equity dips below $2.5M.
8-K
Auditor switch and CFO agreement update
NanoVibronix dismissed Zwick CPA as its auditor on August 12, 2025, due to material weaknesses in internal controls, and appointed Ernst & Young affiliate Kost Forer Gabbay & Kasierer effective August 13. The company also amended CFO Stephen Brown's employment agreement on August 11, setting his base salary at $300,000 with $180,000 severance eligibility after six months. No disagreements marred the auditor switch. This bolsters financial oversight amid going concern doubts.
8-K
NanoVibronix enacts 1-for-10 split
NanoVibronix filed for a 1-for-10 reverse stock split on August 8, 2025, effective August 11, slashing outstanding shares from 7,968,868 to about 796,887 while keeping authorized shares at 40 million. This move, approved by shareholders on July 17, aims to maintain Nasdaq Capital Market listing amid compliance pressures. Trading resumes adjusted on August 12 under NAOV. Yet the split risks further stock price volatility.
8-K
New finance exec appointed
NanoVibronix appointed Rita Silberberg as Executive Vice President of Finance and Chief Accounting Officer, plus Corporate Secretary, effective July 24, 2025. The 49-year-old executive brings over 15 years in corporate finance, US GAAP, and IFRS, with prior CFO stints at Gravity Creative Space and roles at Ernst & Young. Her initial salary starts at NIS 44,000 monthly, rising to NIS 68,750 upon milestones. This bolsters financial leadership amid complex operations.
AVNS
Avanos Medical, Inc.
11.43-0.15
BVS
Bioventus Inc.
6.77-0.17
EMED
Electromedical Technologies, In
0.00+0.00
ENOV
Enovis Corporation
31.99-0.87
NNOX
NANO-X IMAGING LTD
3.74-0.15
NUWE
Nuwellis, Inc.
3.05-0.05
NVCR
NovoCure Limited
13.48+0.11
NVNO
enVVeno Medical Corporation
0.72+0.00
OFIX
Orthofix Medical Inc.
15.32-0.70
SNWV
SANUWAVE Health, Inc.
30.44-0.60